Kite Pharma Archives -

Kite claims a first for CAR-T Tecartus in adult leukaemia

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor

Kite claims a first for CAR-T Tecartus in adult leukaemia

https://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/

News/ News/ Sales and Marketing

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case

Phil Taylor Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, Juno Therapeutics, Kite Pharma, litigation, patent 0 Comment

Gilead Sciences’ Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers

Appeals court reverses $1.2bn judgment against Gilead in BMS CAR-T case

https://pharmaphorum.com/news/appeals-court-reverses-1-2bn-judgment-against-gilead-in-bms-car-t-case/

News/ News/ R&D

Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancer

Phil Taylor Appia Bio, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, Oncology 0 Comment

Gilead Sciences’ Kite Pharma has mapped out another route to the development of allogeneic or ‘off-the-shelf’ cell therapies

Kite takes the ‘Appian way’ to off-the-shelf cell therapies for cancer

https://pharmaphorum.com/news/kite-takes-the-appian-way-to-off-the-shelf-cell-therapies-for-cancer/

T-cells attacking cancer cell illustration of microscopic photos

News/ News/ Oncology

BioNTech grows in cell therapies, buying Kite’s TCR platform

Phil Taylor BioNTech, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, M&A, Oncology 0 Comment

BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19

BioNTech grows in cell therapies, buying Kite’s TCR platform

https://pharmaphorum.com/news/biontech-grows-in-cell-therapies-buying-kites-tcr-platform/

News/ News/ Oncology

Gilead combs Shoreline for NK cell therapies in $2.3bn alliance

Phil Taylor car-nk, cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, natural killer cell, Oncology, Shoreline Bioscience 0 Comment

Gilead Sciences’ cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging

Gilead combs Shoreline for NK cell therapies in $2.3bn alliance

https://pharmaphorum.com/news/gilead-combs-shoreline-for-nk-cell-therapies-in-2-3bn-alliance/

News/ News/ Oncology

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

Phil Taylor acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus 0 Comment

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

Richard Staines Allogene, CAR T, Gilead, Kite Pharma, non-Hodgkin lymphoma, Oncology 0 Comment

In 2018, the former leadership of team from Kite Pharma founded Allogene, on a mission to outdo the

Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy

https://pharmaphorum.com/news/allogene-announces-pivotal-trial/

News/ News/ Oncology

Oxford BioTherapeutics to research cell therapies for Gilead’s Kite

Phil Taylor cell therapy, Gilead Sciences, immuno-oncology, Kite Pharma, Oncology, Oxford BioTherapeutics, partnership 0 Comment

Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch

Oxford BioTherapeutics to research cell therapies for Gilead’s Kite

https://pharmaphorum.com/news/oxford-biotherapeutics-to-research-cell-therapies-for-gileads-kite/

News/ News/ Oncology

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

Phil Taylor CHMP, ema, Gilead Sciences, Kite Pharma, mantle cell lymphoma, Non-Hodgkins Lymphoma 0 Comment

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for

Kite cues up first EMA okay for mantle cell lymphoma CAR-T

https://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/

Trending

Kite Pharma

Login